Why Wegovy Causes Diarrhoea — and What the Evidence Shows

What the trial data tells us about diarrhoea on semaglutide

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks and remains the largest head-to-head evaluation of semaglutide 2.4mg against placebo. Gastrointestinal events were the most commonly reported adverse effects throughout, with diarrhoea occurring considerably more frequently in the semaglutide group than in those receiving placebo. Most episodes were rated mild to moderate in severity. The pattern was consistent with earlier semaglutide research: symptoms clustered around the early weeks of treatment and around dose increases, then tapered off for the majority of participants.

Why does this happen at a biological level? Semaglutide activates GLP-1 receptors found not only in the brain and pancreas but throughout the gastrointestinal tract. That activation slows gastric emptying, which is precisely what reduces appetite, but the same signalling also affects how quickly contents move through the small and large intestine. If you want a fuller picture of whether Wegovy can cause diarrhoea and why it affects some people more than others, that page sets out the mechanisms clearly. If you want to understand why the nausea and diarrhoea often arrive together, our page on why Wegovy causes nausea covers the shared mechanism in detail.

The broader full side-effect picture for Wegovy includes nausea, vomiting, constipation and reflux alongside diarrhoea, all reflecting the same underlying gut biology, not a sign that something has gone wrong with your prescription.

Why the dose-increase schedule matters so much here

Semaglutide's titration schedule (stepping up roughly every four weeks from 0.25mg through to the 2.4mg maintenance dose) exists specifically to reduce the severity of these gastrointestinal effects. Each increase asks the gut to readjust, which is why diarrhoea can return briefly even after it had settled. This is normal physiology, not a warning sign on its own.

The practical upshot: keep hydrated. Diarrhoea pulls fluid from the body faster than people expect, and dehydration on top of an already-reduced appetite can compound fatigue and dizziness. A quick checking habit that costs nothing, glance at the colour of your urine once a day. Pale straw means you're hydrated; anything darker than apple juice suggests you need more water before anything else.

Food choices also interact with this. Large, fatty meals or eating quickly can worsen the effect, partly because a slower-emptying stomach has less tolerance for a heavy load. Smaller portions, eaten more slowly, are consistently better tolerated during the first few months. There is more on managing the day-to-day experience of these early side effects at our Wegovy diarrhoea page, and if you're specifically wondering why this is happening to you in particular, individual variation in gut-receptor density may explain why some people notice it more than others. Semaglutide and Ozempic share the same active molecule, our page on whether Wegovy and Ozempic share the same side effects explains how the profiles compare.

When diarrhoea on Wegovy needs medical attention

Most episodes resolve without any intervention beyond sensible hydration and dietary adjustment. But there are situations where you should contact a doctor or call 111 promptly.

Seek urgent medical help if: diarrhoea is severe and has lasted more than 24 hours without improvement; you cannot keep fluids down and are showing signs of dehydration (extreme thirst, very dark urine, dizziness when standing); or you develop severe abdominal pain that extends to your back, with or without vomiting. That last combination can be a sign of pancreatitis, a known but infrequent serious side effect of GLP-1 medicines. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis for this medicine class, and they ask patients and healthcare professionals to remain alert to it.

Any suspected side effect (including persistent diarrhoea) can be reported directly to the MHRA via the Yellow Card scheme. This reporting genuinely matters: it is how safety signals are detected after a medicine reaches wide use, and patients can report as well as clinicians.

If diarrhoea is manageable but affecting your quality of life, raise it at your next clinical review. Our prescribers discuss side effects as part of the consultation, not as an afterthought, if you have questions before starting treatment, you can speak to our prescribers through a free consultation. Detailed eligibility and treatment options are also set out on our weight-loss treatments overview.